NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

SER

Serina Therapeutics Inc

Jun 30 • 04:00PM ET

6.16

Dollar change -0.01
Percentage change -0.16	%

Healthcare • Biotechnology • USA • AMEX

Peers: MRK LLY BMY JNJ AMGN PFE GILD REGN VRTX BIIB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.94	Insider Own	67.22%	Shs Outstand	9.93M	Perf Week	8.07%
Market Cap	61.40M	Forward P/E	-	EPS next Y	-1.52	Insider Trans	0.00%	Shs Float	3.27M	Perf Month	7.13%
Enterprise Value	57.40M	PEG	-	EPS next Q	-0.49	Inst Own	3.40%	Short Float	0.88%	Perf Quarter	29.68%
Income	-6.28M	P/S	472.31	EPS this Y	-19.87%	Inst Trans	3.52%	Short Ratio	2.12	Perf Half Y	14.07%
Sales	0.13M	P/B	35.97	EPS next Y	16.02%	ROA	-63.92%	Short Interest	0.03M	Perf YTD	22.95%
Book/sh	0.17	P/C	14.38	EPS next 5Y	4.87%	ROE	-	52W High	11.56 -46.74%	Perf Year	-25.24%
Cash/sh	0.43	P/FCF	-	EPS past 3/5Y	42.71% 33.30%	ROIC	-325.67%	52W Low	3.81 61.68%	Perf 3Y	-77.54%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	11.87% -49.63%	Gross Margin	-36.51%	Volatility	8.23% 7.20%	Perf 5Y	-81.04%
Dividend TTM	-	EV/Sales	441.54	EPS Y/Y TTM	55.34%	Oper. Margin	-11951.59%	ATR (14)	0.45	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.45	Sales Y/Y TTM	34.04%	Profit Margin	-4983.33%	RSI (14)	57.52	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.45	EPS Q/Q	84.60%	SMA20	4.21%	Beta	0.72	Target Price	11.00
Payout	-	Debt/Eq	0.24	Sales Q/Q	-100.00%	SMA50	6.38%	Rel Volume	3.70	Prev Close	6.17
Employees	13	LT Debt/Eq	0.14	Earnings	May 08 AMC	SMA200	10.82%	Avg Volume	13.65K	Price	6.16
IPO	Nov 29, 2018	Option/Short	No / Yes	EPS/Sales Surpr.	20.97% -	Trades		Volume	50,516	Change	-0.16%

Jun-23-25 07:24PM	Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025 (GlobeNewswire) +5.95%
Jun-17-25 08:30PM	UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42 (GlobeNewswire)
06:00AM	Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42 (GlobeNewswire)
Jun-09-25 04:05PM	Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?" (GlobeNewswire)
May-22-25 04:50PM	Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors (GlobeNewswire) +8.87%
03:15PM	Loading…
May-14-25 03:15PM	Serina Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire)
May-08-25 04:23PM	Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
Apr-29-25 06:00AM	Serina Therapeutics to Present at JonesResearch Virtual CNS Day (GlobeNewswire)
Apr-15-25 06:30AM	Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit (GlobeNewswire)
Apr-08-25 04:30PM	Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease (GlobeNewswire)
Apr-07-25 06:30AM	Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference (GlobeNewswire)
Mar-24-25 04:30PM	Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
06:30AM	Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting (GlobeNewswire)
Feb-12-25 04:15PM	Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors (GlobeNewswire)
Feb-03-25 04:30PM	Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients (GlobeNewswire) -5.91%
04:05PM	Loading…
Jan-15-25 04:05PM	Serina Therapeutics Announces Sale of UniverXome Subsidiary (GlobeNewswire)
Jan-14-25 05:25PM	Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors (GlobeNewswire)
Dec-16-24 06:00AM	Serina Therapeutics to Present at Tribe Public's Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024 (GlobeNewswire) -7.98%
Dec-11-24 06:05AM	Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity and Toxicity Summit (GlobeNewswire) -9.16%
06:05AM	Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit (GlobeNewswire)
Dec-02-24 05:22PM	Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients (GlobeNewswire) -9.52% +19.16%
Nov-12-24 05:00PM	Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire)
Nov-11-24 05:40PM	Serina Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) +20.87%
Oct-02-24 08:30AM	Serina Therapeutics to Present at the 14th Annual Injectables Summit (GlobeNewswire)
Sep-04-24 06:42PM	Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-20-24 07:01PM	Director Gregory Bailey Acquires 19,200 Shares of Serina Therapeutics Inc (SER) (GuruFocus.com)
Aug-09-24 04:15PM	Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire) -5.17% -10.13%
Jul-29-24 08:30AM	Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit (GlobeNewswire)
Jul-18-24 05:00PM	Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation (GlobeNewswire) -18.15% +9.84%
May-15-24 07:30AM	Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse® for Advanced Parkinsons Disease (GlobeNewswire)
04:05PM	Loading…
May-14-24 04:05PM	Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire) +11.13%
Apr-17-24 04:05PM	Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman (GlobeNewswire) -9.64%
Mar-26-24 05:04PM	Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics (GlobeNewswire) -11.90% +33.98%

Serina Therapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the research and development of polymer technology. Its POZ technology is designed to optimize drug delivery to maximize compliance, therapeutic outcomes, safety, and quality of life for patients. It also offers drugs to treat neurological diseases, cancer, and pain. The company was founded by J. Milton Harris and Michael D. Bentley on March 26, 2024 and is headquartered in Huntsville, AL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Moreadith Randall	Officer	Jun 30 '25	Proposed Sale	5.78	99,674	576,056		Jun 30 04:28 PM
Bailey Gregory	Director	Dec 17 '24	Buy	4.59	3,866	17,745	67,243	Dec 19 04:05 PM
Bailey Gregory	Director	Sep 20 '24	Buy	6.03	1,137	6,851	63,377	Sep 24 04:30 PM
Bailey Gregory	Director	Sep 19 '24	Buy	6.11	11,679	71,384	62,240	Sep 20 06:59 PM
Bailey Gregory	Director	Sep 18 '24	Buy	6.23	2,709	16,873	50,561	Sep 20 06:59 PM
MINTZ STEVEN	Director	Sep 12 '24	Buy	6.47	6,000	38,814	17,443	Sep 16 06:53 PM
Bailey Gregory	Director	Aug 20 '24	Buy	8.25	1,776	14,652	47,582	Aug 22 05:27 PM
Bailey Gregory	Director	Aug 19 '24	Buy	7.93	6,400	50,760	45,806	Aug 20 04:35 PM
Bailey Gregory	Director	Aug 16 '24	Buy	7.31	6,400	46,780	39,406	Aug 20 04:35 PM
Bailey Gregory	Director	Aug 15 '24	Buy	6.65	6,400	42,577	33,006	Aug 20 04:35 PM
MINTZ STEVEN	Director	Aug 15 '24	Buy	6.59	7,593	50,033	11,443	Aug 19 06:55 PM
MINTZ STEVEN	Director	Aug 15 '24	Buy	6.59	1,350	8,896	12,257	Aug 19 06:55 PM
Bailey Gregory	Director	Aug 14 '24	Buy	7.07	6,400	45,228	26,606	Aug 16 04:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SER

Serina Therapeutics Inc

Upgrade your FINVIZ experience